Small volumes, deep insights: longitudinal plasma EV multi-omics in very preterm infants

Nicole Grinovero[1†], Francesca Antonini[1†], Martina Bartolucci[1], Lucilla Rossi[1], Gianvittorio Luria[1], Maurizio Bruschi[2,3], Sonia Spinelli[2], Gino Tripodi[4], Chiara Andreato[5,6], Francesco Vinci[5,6], Luca Antonio Ramenghi[5,6‡], Chiara Lavarello[1*‡], Andrea Petretto[1‡]

[1] Core Facility for Omics Sciences, IRCCS Istituto Giannina Gaslini, Genoa, Italy
[2] Unit of Nephrology, Dialysis, and Transplantation and Laboratory of Molecular Nephrology, IRCCS Istituto Giannina Gaslini, Genoa, Italy
[3] Department of Experimental Medicine (DIMES), University of Genoa, Italy
[4] Immunohematology and Transfusion Medicine Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
[5] Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Italy
[6] Neonatal Intensive Care Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy

[†] These authors contributed equally to this work.
[‡] These authors jointly supervised this work.
* Correspondence to: Chiara Lavarello (chiaralavarello@gaslini.org)

Abstract

Very preterm birth disrupts critical fetal developmental programs, yet the systemic molecular trajectories driving extrauterine adaptation remain poorly defined. Although extracellular vesicles (EVs) represent informative systemic compartments, comprehensive multi-omics is constrained by the small plasma volumes safely obtainable from neonates. Here, we adapted a magnetic bead-based framework (Mag-Net) to enable parallel EV proteomics and lipidomics from the same EV-enriched preparation using 10 µL of plasma. Across 74 longitudinal samples collected from birth to term-equivalent age, we quantified 1,528 EV-associated proteins and 421 lipid species. The EV proteome shifted from early translation and metabolic programs toward progressive immune competence, while the lipidome underwent selective structural remodeling enriched in triacylglycerols and ether-linked phosphatidylcholines. Cross-omics integration identified coordinated protein-lipid modules associated with clinical phenotypes, including brain injury. This study demonstrates that parallel EV proteomic-lipidomic profiling from microliter plasma volumes is feasible and captures coordinated developmental and clinically relevant programs in very preterm infants.

37   *Keywords: Extracellular vesicles, Multi-omics, Preterm birth, Liquid biopsy, Brain injury*

39   Introduction

Preterm birth affects approximately 13-15 million infants each year worldwide and remains a

leading cause of neonatal mortality and long-term neurodevelopmental impairment[1]. Infants born

very preterm (<32 weeks of gestation) undergo extrauterine adaptation during the third trimester, a

critical window marked by the rapid and coordinated maturation of neural, immune and metabolic

systems[2,3]. This transition interrupts tightly regulated fetal programs, forcing maturation to unfold

under fundamentally different biological conditions shaped by altered oxygen exposure,

inflammation, and modified nutritional inputs. As a result, postnatal development in very preterm

infants does not simply represent an accelerated version of normal maturation, but unfolds under

different biological constraints[4,5].

During the first weeks of life, intrinsic maturation occurs alongside clinical exposures such as

respiratory support, infection and hemodynamic instability. Because developmental timing and

stress responses are tightly intertwined, cross-sectional comparisons provide limited insight into

the molecular organization of early adaptation. In addition, inter-individual variability is substantial

in very preterm cohorts, reflecting differences in gestational age and clinical course. Longitudinal

designs, in which each infant serves as their own reference, are therefore essential to distinguish

structured developmental trajectories from reactive changes linked to clinical events[6].

Extracellular vesicles (EVs) provide a biologically relevant analytically tractable compartment for

this purpose. EVs are membrane-bound particles released by most cell types and mediate

intercellular communication through the transfer of proteins, lipids and nucleic acids[7,8]. As

circulating, cell-derived structures, they integrate signals across tissues and can be accessed

through minimally invasive plasma sampling, making them well suited for longitudinal studies in

neonatal populations[9,10]. Importantly, EVs are structured molecular entities. Their lipid bilayer is

selectively assembled and enriched in specific phospholipids and sphingolipids that influence

vesicle curvature, stability and fusion, while membrane-associated and luminal proteins regulate

trafficking and signaling[11]. Because membrane lipids and proteins are functionally linked, parallel

analysis of EV proteomes and lipidomes enables an integrated view of both structural and

signaling aspects of systemic adaptation.

Despite this potential, EV analysis in plasma poses well-recognized technical challenges. EVs

represent only a small fraction of circulating particles and are outnumbered by lipoproteins and

abundant soluble proteins. Overlap in size and density complicates separation, and incomplete

resolution is particularly problematic for lipidomics, where co-isolated lipoprotein lipids can

dominate the measured signal[12,13]. Benchmarking studies have shown that isolation strategies

involve trade-offs between purity and yield: precipitation-based methods often provide higher
recovery but increased contamination, whereas density-gradient or size-exclusion approaches
improve purity but reduce yield and require larger input volumes[12].
These limitations are amplified in neonatal research, where available plasma volumes are
inherently limited and repeated sampling must remain minimally invasive to allow longitudinal
follow-up. Many EV isolation workflows require hundreds of microliters to milliliters of plasma and
multiple processing steps, making them poorly suited for fragile populations. In addition, most EV
multi-omics studies process proteomics and lipidomics separately, dividing enriched material into
aliquots. When starting volumes are small, this reduces analytical depth and disrupts the natural
coupling between membrane composition and protein cargo. Although parallel EV proteomics and
lipidomics have been demonstrated in adult plasma using larger-volume, density-gradient-based
workflows[13], integrated proteomic-lipidomic profiling from microliter-scale plasma inputs in a
longitudinal neonatal setting has not been established.
87
To address part of the isolation challenge, a strong anion exchange (SAX)-based enrichment
strategy (Mag-Net) was recently developed for plasma proteomics[14]. By exploiting the net negative
surface charge of EV membranes, Mag-Net enables selective enrichment of vesicle-associated
material from complex plasma matrices while reducing interference from highly abundant soluble
proteins. This workflow has been validated for deep plasma EV proteome profiling and provides an
automated, scalable platform compatible with clinical samples[14].
In this study, we build on the Mag-Net framework and extend it to enable integrated proteomic and
lipidomic analysis from plasma micro-volumes. We evaluate and refine the workflow using 5 and
10 µL plasma inputs, volumes compatible with longitudinal sampling in very preterm infants, and
optimize the downstream extraction strategy to enable monophasic recovery of proteins and lipids
from the same EV preparation. This approach preserves cross-layer molecular relationships
without splitting the input material and demonstrates the feasibility of parallel EV multi-omics from
microliter-scale plasma volumes.
After technical validation and benchmarking against conserved circulating EV signatures[13], we
apply this optimized workflow longitudinally in a clinically characterized cohort of very preterm
infants from birth to term-equivalent age. Using linear mixed-effects modeling and cross-omics
network integration, we characterize coordinated EV molecular trajectories during early
extrauterine adaptation and examine their associations with clinical outcomes, with particular
attention to brain injury.
107

Results

Optimization of an integrated EV proteomic and lipidomic workflow from plasma micro-volumes

Integrated clinical multi-omics in fragile populations, such as neonates or patients with rare diseases, is often constrained by minimal sample availability. To enable simultaneous protein and lipid profiling under these micro-volume conditions, we adapted the previously established Mag-Net workflow[14] – originally validated for plasma proteomics – to support parallel analysis from as little as 5-10 µL of plasma. While preserving the upstream strong anion exchange (SAX)-based EV enrichment step, optimization focused on the downstream extraction strategy to ensure compatibility with both analytes. We compared three monophasic extraction chemistries: methanol (MeOH), isopropanol (IPA), and a 1-butanol/acetonitrile/water mixture (3:1:1, v/v), based on the Bead-enabled Accelerated Monophasic Multi-omics (BAMM) approach[15]. In all conditions, solvent-mediated membrane disruption was coupled with on-bead protein aggregation capture (PAC), allowing coordinated recovery of lipids and proteins from the same EV-enriched preparation.

Proteomic depth remained stable across extraction strategies and input volumes (**Fig. 1a**). At 10 µL of plasma input, we identified 866-992 protein groups, with only minor losses in coverage when scaling down to 5 µL. In contrast, direct digestion of whole plasma ("neat") yielded markedly lower depth (308 protein groups), confirming that SAX-based enrichment significantly increases the detectable complexity of the EV-associated proteome. Quantitative reproducibility was consistently high, with most proteins exhibiting a coefficient of variation (CV) < 20% (**Fig. 1b**). Furthermore, concordance with the standard Mag-Net implementation remained strong (Pearson r = 0.89-0.95; **Fig. 1c**), and the preservation of the global EV-associated proteomic landscape was further supported by correlation structure and protein overlap analysis (**Fig. S1**).

Conversely, lipidomic performance was more sensitive to the choice of extraction solvent. Across conditions, we detected up to 308 lipid species in positive mode and 108 in negative mode (**Fig. S2**). While total feature counts were broadly comparable, restricting the analysis to quantitatively robust signals (intensity > 1×10□) revealed solvent-dependent differences (**Fig. 1e**; **Fig. S2**). BAMM extraction consistently yielded the highest lipid coverage in positive mode and the lowest CV values (**Fig. 1f**), reflecting superior quantitative reproducibility. Notably, lipid class distributions remained stable across solvents (**Fig. S2**), indicating that extraction chemistry primarily influenced detection depth rather than inducing systematic compositional bias.

To verify that these molecular profiles reflect selective EV enrichment rather than plasma carryover, we benchmarked our dataset against a conserved circulating EV atlas defined by Rai et al. using density-gradient fractionation[13]. Of the 182 highly conserved EV proteins reported in that study, 168 (92%) were identified in our dataset. These markers showed coherent enrichment in

Mag-Net preparations relative to direct plasma digestion, while abundant non-EV plasma proteins
were strongly depleted (**Fig. 1d**). At the lipid level, 9 of the 52 conserved EV lipid features
described in the reference atlas were detected; although the absolute overlap was lower than for
proteins, these features were consistently detected across all Mag-Net conditions, with BAMM 10
µL displaying the most robust profile (**Fig. S2**). Collectively, these data demonstrate that the
adapted Mag-Net-based workflow recapitulates a conserved EV molecular signature, with BAMM
extraction at 10 µL input providing the optimal balance of lipidomic robustness and proteomic
integrity.
153
Longitudinal evolution of the plasma EV proteome and lipidome across very preterm
development
With the optimized EV multi-omics workflow established, we investigated how circulating EV
molecular programs evolve during early extrauterine adaptation. We applied the method to a
longitudinal cohort of 16 very preterm infants (<32 weeks gestational age) followed from birth to
term-equivalent age (TEA; 40 weeks postmenstrual age). TEA serves as a critical clinical reference
point, representing the stage at which a preterm infant reaches the developmental maturity of a
term-born newborn.
Plasma samples were collected at five predefined timepoints: birth (T0), 48-72 hours (T1), 7 days
(T2), 33 weeks postmenstrual age (T3), and TEA (T4). While all 16 infants contributed samples for
the T0-T3 interval, 10 were followed up to the final TEA milestone. The longitudinal design and
analytical workflow are summarized in **Fig. 2a**, and clinical characteristics are reported in **Table 1**.
Parallel analysis of proteins and lipids from each sample enabled within-subject tracking of
coordinated multi-omic trajectories over time. Based on the superior coverage and quantitative
robustness observed during our technical benchmarking, longitudinal lipidomic profiling was
prioritized in positive ionization mode to ensure maximum analytical depth across the cohort.
After quality filtering, we retained 1,528 EV-associated protein groups and 421 unique lipid species
for longitudinal analysis. Post-filter quantification depth per sample remained stable across
timepoints in both omics layers (**Fig. S3**), supporting consistent analytical coverage throughout the
longitudinal series. The EV-associated proteome spanned a wide dynamic range (**Fig. 2b**) and
showed significant over-representation of extracellular and vesicle-related compartments,
consistent with its EV origin (**Fig. 2c**). In parallel, the lipidomic profile revealed a membrane-
enriched composition dominated by glycerophospholipids and sphingolipids, with sphingomyelins
as the predominant lipid class (**Fig. 2d**).
To characterize the systematic remodeling of proteomic and lipidomic profiles, we employed a
linear mixed-effects modeling (LMM) framework. This approach accounted for the longitudinal
design by incorporating infant-specific random intercepts to model within-subject correlations over
time. Sampling timepoints (T0-T4) were treated as fixed effects to capture developmental trends,

while gestational age at birth was included as a covariate, as it represents a major source of
biological heterogeneity in very preterm cohorts and strongly influences baseline molecular
profiles. For each molecular feature, we tested for a global effect of time and quantified the primary
developmental shift by contrasting TEA (T4) against birth (T0), using the Benjamini-Hochberg (BH)
procedure to control for multiple testing.
187
Extensive postnatal remodeling of the circulating EV proteome
Applying the LMM framework revealed a profound temporal transformation of the plasma EV
proteome following very preterm birth. Overall, 57% of the quantified proteins (875 of 1,528)
exhibited a significant global effect of time (FDR < 0.05), indicating that the majority of EV cargo is
actively and dynamically regulated during the first weeks of extrauterine life.
Unsupervised hierarchical clustering of these time-regulated proteins resolved four distinct clusters
that follow two primary, opposing trajectories: proteins that progressively decreased from birth
toward maturation (clusters 1A and 1B) and proteins that steadily increased over time (clusters 2A
and 2B) (**Fig. 3a,b**). The presence of these highly coordinated trajectories suggests that
longitudinal EV proteomic shifts are coherent and directional, rather than reflecting unspecific
physiological variability.
To quantify the magnitude of this transition, we focused on the net developmental shift between
birth and TEA. We identified 439 proteins significantly downregulated and 127 proteins significantly
upregulated at TEA (FDR < 0.05 and $|\beta| > 0.58$, corresponding to approximately ≥1.5-fold change;
Fig. 3c). Proteins that decreased toward TEA were central to RNA metabolism, translation, and
early growth-related processes (**Fig. 3e**). This "early-life" signature included core components of
the translational machinery, such as RPS6 and EIF4A2, alongside the classic fetal marker alpha-
fetoprotein (AFP), all of which showed steep declines across the five timepoints (**Fig. 3d**).
In striking contrast, the proteomic profile at TEA was characterized by a mature systemic signature.
Proteins increasing toward TEA were significantly enriched for immune-related functions,
specifically the complement cascade, immunoglobulin-mediated responses, and adaptive immunity
(**Fig. 3e**). Representative markers of this maturation – including complement component C9, the
anticoagulant protein S (PROS1), and the lipid transporter MTTP – exhibited linear increases
across postnatal development (**Fig. 3d**). Collectively, these findings highlight a coordinated
functional transition of the EV proteome from a translation-heavy growth program at birth toward a
robust immune-competent profile at term-equivalent age.
214
Selective structural and metabolic remodeling of the EV lipidome
We next evaluated the longitudinal evolution of the plasma EV lipidome using the same LMM
framework. While lipidomic remodeling involved a more targeted subset of features compared to
the proteome – with 100 of 421 quantified species showing a significant global effect of time (FDR

< 0.05) – the changes were highly structured and coordinated (**Fig. 4a**). Unsupervised hierarchical
clustering resolved these regulated lipids into four distinct developmental trajectories, each
comprising species from multiple chemical classes (**Fig. 4b**). This modular organization indicates
that EV lipidomic shifts are governed by coordinated metabolic programs rather than uniform,
class-wide abundance changes.

The developmental transition to TEA was marked by the significant upregulation of 41 lipid species
and the downregulation of 22 (FDR < 0.05 and $|\beta| > 0.58$, corresponding to approximately ≥1.5-fold
change; **Fig. 4c**). Lipids increasing over development were dominated by triacylglycerols (TG),
ether-linked phosphatidylcholines (PC O-), and specific sphingomyelins (SM). Among the strongest
increases were SM 28:1;O2 and ether-linked species such as PC O-39:8 and PC O-37:8,
alongside multiple TG species (**Fig. 4c**). These shifts are consistent with a progressive enrichment
of neutral lipid cargo and a selective remodeling of EV membrane architecture.

Conversely, lipids that declined toward TEA were significantly enriched for diacyl PCs,
phosphatidylserines (PS), diacylglycerols (DG), and long-chain SMs. Representative examples
included PC 32:1 and PC 31:0, which showed the strongest negative effect sizes, as well as long-
chain SM such as SM 36:0;O2 and SM 44:1;O2. Notably, lipid regulation was highly structural-
specific rather than class-uniform. Specifically, SMs displayed opposite trends depending on chain
length, with shorter species increasing and longer species decreasing over development, while
PCs had divergent behavior according to linkage type, with ether-linked species preferentially
increasing and diacyl species preferentially decreasing toward TEA.

To place these compositional changes into a functional context, we performed lipid ontology
(LION) enrichment analysis based on the TEA vs birth β coefficients ($\log_2$ fold-change estimates)
(**Fig. 4d**). Lipids enriched at T4 were associated with annotations related to lipid storage and lipid
droplet biology. In contrast, lipids reduced over time were preferentially associated with membrane
structural properties, including bilayer thickness and intrinsic curvature.

Finally, we mapped the regulated species from major membrane classes (PC, PC O-, and SM)
onto carbon number-double bond space (**Fig. 4e**). This analysis revealed that birth- and TEA-
enriched species occupy distinct regions of structural space within each class. Importantly, these
shifts were class-specific and did not reflect a uniform global trend toward increased chain length
or saturation, but rather a selective redistribution among molecular species.

Together, these analyses demonstrate that postnatal development in very preterm infants is
characterized by a progressive and highly coordinated remodeling of the plasma EV composition
across both omics layers. While proteomic changes are widespread and involve fundamental shifts
in pathways related to growth and immune maturation, lipidomic changes are more selective,
reflecting a sophisticated redistribution among specific structural species. Overall, these findings
establish that plasma EVs serve as high-resolution molecular snapshots of the systemic

developmental changes occurring during the critical preterm period, providing a robust platform for
tracking extrauterine adaptation.
258

Network-based integration reveals coordinated multi-omic EV modules
To characterize the systemic architecture of EV maturation, we integrated the proteomic and
lipidomic layers using a cross-omics correlation network approach (**Fig. 5a**). We focused on the
dynamically regulated components of EV remodeling by including only the 875 proteins and 100
lipids that exhibited significant temporal trajectories in our longitudinal LMM analysis. Inter-omic
coordination was assessed by computing pairwise Spearman correlations (ρ) across paired
longitudinal samples. By restricting the network to cross-layer associations and to features with a
significant time effect (FDR < 0.05), we intentionally captured coordinated protein–lipid co-variation
along the shared developmental trajectory, rather than within-layer structure or correlations driven
by absolute abundance. After multiple-testing correction and effect-size filtering ($|\rho| \geq 0.35$, FDR <
0.05), the resulting network revealed a bimodal distribution of associations, with clear topological
separation between positive and negative correlations (**Fig. 5b**).
271

Using Louvain community detection, we resolved the network into five distinct cross-omic modules
(M1-M5), each representing a set of proteins and lipids with coherent longitudinal behavior (**Fig.**
5a, c). While proteins constituted the majority of nodes, lipids were consistently integrated within
each module rather than forming isolated clusters, highlighting the tight biochemical coupling of the
EV multi-ome. Functional annotation of protein components within each module identified distinct
biological hallmarks of preterm development (**Fig. 5d**). Module M1, the largest community,
reflected a systemic shift in neonatal metabolism through its enrichment in macromolecule
catabolism and intracellular organization, effectively capturing the progressive decline of growth-
associated cargo as the infant adapts to the extrauterine environment. The maturation of the
neonatal immune system was divided into two distinct programs: module M2 was characterized by
endocytosis and complement-mediated responses, hallmarks of the innate immune system, while
module M3 focused on the expansion of the adaptive immune repertoire, specifically
immunoglobulin-mediated signaling. The remaining modules highlighted the biosynthetic and
structural demands of development; module M4 was associated with ribosomal biogenesis and
cytoplasmic translation, whereas module M5 centered on extracellular matrix organization and
tissue remodeling, suggesting a direct link between EV molecular cargo and the maturation of
systemic tissue architecture.
289

Association of integrated EV molecular modules with clinical phenotypes
To evaluate the clinical relevance of the integrated EV programs, we interrogated the associations
between cross-omics molecular modules and neonatal outcomes using a CAMERA-based

competitive gene set framework (**Fig. 6a**). By incorporating linear mixed-effects modeling with
duplicate correlation, we accounted for the longitudinal nature of the data while adjusting for
gestational age at birth. This module-level strategy increased statistical power to detect
coordinated molecular programs that remained below the significance threshold in single-feature
analyses.
298
Module M1 displayed a highly significant association with hemorrhagic brain lesions (FDR = 1.6 ×
$10^-\square$). Although the global module trajectory reflected a progressive decline in metabolic and
proteostatic cargo, its leading-edge signal was driven by a compensatory increase in complement
regulators C4BPA (β = 1.44) and C4BPB (β = 0.82), contrasted with a marked depletion of the
hemoglobin subunit HBM (β = –0.74) (**Fig. 6b**). This internal divergence suggests selective
remodeling of EV cargo in the context of hemorrhagic injury, with complement modulation
emerging as a dominant adaptive feature.
In parallel, Module M3 exhibited consistent positive associations with both hemorrhagic lesions and
the broader category of any brain lesion, including white matter injury (FDR = 3.7 × $10^-\square$) (**Fig.**
6a,c). This module reflected a sustained neuroinflammatory and adaptive immune signature,
characterized by coordinated upregulation of immunoglobulin families and stress-response
mediators such as NIBAN1 (β = 0.55) and the immunoproteasome subunit PSMB8 (β = 0.50),
alongside reduced levels of the adhesion molecule SELL (β = –0.49). These trajectories indicate
altered leukocyte activation and trafficking dynamics associated with brain injury.
The module-level framework further uncovered concerted lipidomic shifts that were not detectable
at the single-feature level (**Fig. 6a,d**). Module M2 lipids were negatively associated with
hemorrhagic lesions (FDR = 0.02), reflecting coordinated reductions in membrane-related species,
including ether-linked phosphatidylcholines such as PC O-37:8 (β = –0.96) and PC O-39:8 (β =
–0.79). Conversely, lipid components within module M3 were positively associated with systemic
stress phenotypes, including sepsis (FDR = 0.04) and mechanical ventilation (FDR = 0.01).
Representative species such as PC 33:1 and PC 32:1 showed sustained elevations in affected
infants (**Fig. 6d**), accompanied by increases in diacylglycerols, consistent with lipid mobilization
during inflammatory and respiratory stress.
Collectively, these results demonstrate that clinical phenotypes in very preterm infants are more
robustly captured at the level of integrated EV molecular modules than individual features. Notably,
the cross-layer convergence of Module M3 across proteins and lipids reinforces a coordinated link
between adaptive immune activation and systemic inflammatory outcomes, highlighting the value
of multi-omics integration to resolve distributed biological programs underlying neonatal pathology.
327

Discussion

Very preterm birth displaces a critical phase of third-trimester maturation into an extrauterine environment characterized by abrupt shifts in oxygen exposure, inflammation, nutrition and intensive care interventions. Longitudinal systems studies have shown that postnatal immune development follows highly ordered and reproducible trajectories, even in preterm infants[6,16,17]. Dissecting intrinsic developmental timing from superimposed clinical stress therefore requires molecular readouts that are both temporally sensitive and biologically specific. Here, we demonstrate that plasma EVs provide such a compartment. By extending Mag-Net enrichment[14] to enable integrated proteomic and lipidomic profiling from 10 µL plasma, and applying this framework from birth to term-equivalent age, we reconstruct structured EV trajectories and identify cross-omics modules associated with clinically relevant phenotypes, most prominently brain injury.

A first advance is methodological, with direct implications for biological interpretation. Plasma EV profiling is constrained not only by minimal input volumes but also by incomplete separation from abundant non-EV particles, particularly lipoproteins. High-resolution plasma fractionation studies now define conserved EV protein and lipid features alongside non-EV hallmarks[13], and demonstrate that lipoproteins can physically associate with EVs, forming hybrid nanoparticle complexes[18]. Methodological work further shows that combined size- and density-based approaches improve purity but cannot completely eliminate co-isolates[19]. Within this context, extracting proteins and lipids from the same EV preparation preserves the intrinsic coupling between membrane composition and protein cargo, strengthening cross-layer interpretation while acknowledging known plasma complexities.

Biologically, EV remodeling across early postnatal life is highly structured. More than half of quantified EV proteins display significant temporal dynamics, resolving into two dominant programs: a birth-enriched profile dominated by translation and RNA metabolism, and a progressively increasing immune program enriched for complement and immunoglobulin-associated functions. This transition mirrors systems-level neonatal studies demonstrating rapid, time-driven immune reorganization, with complement pathways among the most reproducibly regulated components in early life[6,20]. In large extremely preterm cohorts, postnatal age explains a substantial proportion of circulating proteomic variance, exceeding gestational age effects beyond the earliest window[17]. The EV trajectories observed here are therefore consistent with a broader temporal architecture of immune ontogeny, but captured within a selectively packaged vesicular compartment rather than bulk plasma.

The immune "ramp" we observe is not generic. Longitudinal plasma proteomics demonstrates coordinated early increases in classical and terminal complement components, rising IgM, and declining maternally derived IgG during the first week of life[20]. Our EV modules enriched for

complement and immunoglobulin-linked programs align with these dynamics, suggesting that EV
cargo reflects structured maturation of innate and adaptive immune interfaces rather than
nonspecific inflammation.
The EV lipidome follows a complementary but distinct pattern. Although fewer lipid species are
time-structured, remodeling is clearly species- and structure-dependent. Enrichment toward TEA of
triacylglycerols and ether-linked phosphatidylcholines, together with chain-length and linkage-
specific redistribution within membrane classes, argues against uniform class-wide drift. Ether
lipids are mechanistically linked to exosome biogenesis: modulation of ether-lipid synthesis alters
vesicle release and composition[21], and plasmalogen enrichment influences membrane biophysical
properties[22]. These data support the interpretation that ether-PC increases may reflect regulated
membrane remodeling during EV maturation. At the same time, neutral lipid signals must be
interpreted cautiously. LDL particles can co-purify and associate with EVs[18,23], and TG species are
enriched in non-EV plasma fractions[13]. Conversely, lipid-rich exosome-sized vesicles with immuno-
metabolic functions have been described[24]. Our interpretation therefore remains balanced: TG
enrichment may reflect both regulated EV-associated biology and the evolving nanoparticle
environment of neonatal plasma.
381
Integration of proteomic and lipidomic layers provides the clearest insight. By restricting network
construction to temporally regulated features and modeling cross-layer correlations, we identify five
modules summarizing coordinated longitudinal behavior. Network-based dimensionality reduction
reduces multiple testing burden and yields biologically coherent units that are more stable than
single features in small, heterogeneous cohorts. In our dataset, modules partition immune
maturation into distinct programs and capture distributed lipid shifts that are not evident at the
single-molecule level. This module-level organization transforms high-dimensional data into
interpretable biological states.
Clinically, module-phenotype associations converge on brain injury. Complement provides a
biologically plausible bridge between systemic inflammation and immature white matter
vulnerability. In neonatal models, activation of the C3a-C3aR axis impairs oligodendrocyte
precursor maturation and promotes hypomyelination[25]. Genetic disruption of classical pathway
components such as C1q reduces hypoxic-ischemic brain injury in neonatal models[26,27], while C5a
signaling contributes to cortical injury in experimental preterm birth[28]. Complement components
also participate in glia-mediated neurotoxicity, including C1q-driven astrocyte activation[29]. These
mechanistic data support the plausibility that EV modules enriched for complement components
reflect systemic states linked to brain vulnerability.
Translational work further supports EV-mediated inter-organ communication in prematurity. In
preterm infants, higher oxygen exposure associates with increased circulating EV cargo containing
inflammasome components, and adoptive transfer of such EVs induces lung and brain injury

phenotypes in neonatal models[30]. EV cargo has also been linked to bronchopulmonary dysplasia

severity with functional validation[31]. Together, these findings support the concept that circulating

EVs can report and potentially mediate lung-immune-brain interactions. Within this framework,

associations between our EV modules, respiratory support and brain injury are biologically

coherent.

An additional interpretive layer concerns the plasma protein corona. EVs incubated in plasma

acquire surface-associated proteins, including complement components and immunoglobulins[32].

This is particularly relevant in plasma, where EV surface-associated proteins may represent vesicle

biology and the surrounding environment simultaneously. Importantly, such coronas modulate

immune cell uptake and trafficking[33]. Complement- and Ig-rich modules may therefore reflect a

combination of intrinsic cargo remodeling and altered opsonization dynamics, both relevant to

neonatal inflammation and sepsis. Together, these observations indicate that immune-enriched EV

modules provide a structured representation of vesicle-associated immune remodeling.

Several limitations define the scope of inference. Plasma EV preparations remain heterogeneous

in subtype and cellular origin, and non-EV contributions cannot be fully excluded, particularly in

lipid space. Our aim was to characterize an EV-enriched systemic compartment rather than assign

tissue specificity, although EV proteomics has demonstrated tissue-enriched signatures in plasma

under optimized conditions[34]. Nutritional transitions plausibly influence both immune and lipid

trajectories. Although longitudinal mixed-effects modeling and module-level statistics mitigate

limited cohort size and unbalanced late sampling, independent validation will be required before

clinical translation.

In summary, integrated EV proteomic–lipidomic profiling from 10 µL of plasma captures coherent,

time-structured molecular programs in very preterm infants. By enabling parallel recovery of

proteins and lipids from the same micro-volume preparation, this workflow preserves cross-layer

biological relationships under sampling conditions that are realistic in the NICU setting. EV proteins

trace a coordinated shift from growth-associated translation toward immune competence,

consistent with established patterns of neonatal immune ontogeny[6,16]. EV lipids undergo selective,

structure-dependent remodeling compatible with regulated membrane biology[21], while remaining

interpretable within the known constraints of plasma nanoparticle complexity. Cross-omics

modules condense these longitudinal dynamics into stable and biologically meaningful units and

reveal clinically relevant programs associated with brain injury and systemic stress. Together,

these findings demonstrate that ultra-low-volume EV multi-omics is not only technically feasible,

but capable of resolving structured developmental and injury-related trajectories, providing a

scalable framework for longitudinal molecular profiling in neonatal medicine.

Methods

Cohort description

This prospective, longitudinal study included 16 very preterm infants born at <32 weeks of gestational age and admitted to the Neonatal Pathology and Intensive Care Unit of IRCCS Istituto Giannina Gaslini (Genoa, Italy). Infants were consecutively enrolled between November 2022 and November 2023 and followed from birth to term-equivalent age (40 weeks postmenstrual age) according to a predefined study protocol.

A total of 74 plasma samples were collected across five scheduled timepoints (T0-T4). Only infants with samples available at a minimum of four timepoints were included in longitudinal analyses.

Demographic and clinical data were collected from electronic medical records. Baseline characteristics were selected a priori based on relevance to neonatal maturation and availability in the clinical dataset. A summary of demographic and clinical characteristics is provided in **Table 1**.

Neurological status was assessed using routine clinical neuroimaging, including cranial ultrasound and, when clinically indicated, magnetic resonance imaging. Brain injury was defined as the presence of any documented brain lesion and recorded as a binary variable. When present, lesions were classified descriptively as hemorrhagic or white matter injury.

The study was conducted in accordance with the Declaration of Helsinki and approved by the Liguria Regional Ethics Committee (approval ID: 469/2021 – DB ID 11730). Written informed consent was obtained from the parents or legal guardians prior to enrollment.

Patients characteristics	
Gestational age at birth (weeks)	29.5 [28.5–31.2]
Birth weight (g)	1,255 [849–1,561]
Male sex	9 (56.2%)
Any brain lesion	8 (50.0%)
Hemorrhagic brain lesion	6 (37.5%)
White matter lesion	2 (12.5%)
Sepsis	8 (50.0%)
Mechanical ventilation	9 (56.2%)
Data are presented as median [Q1–Q3] or n (%). N = 16.	

Table 1: Baseline demographic and clinical characteristics of the study cohort (N = 16). Continuous variables are reported as median [Q1–Q3] and categorical variables as n (%). Neurological outcomes are presented hierarchically, with overall brain lesion status reported as the primary outcome and lesion subtypes described separately.

Nutritional management

All infants were managed according to a standardized institutional nutritional protocol applied consistently across the cohort. Parenteral nutrition was initiated immediately after birth with amino acids and 10% glucose. At approximately 24 hours of life, a multicomponent lipid emulsion (SMOFlipid; soybean oil, medium-chain triglycerides, olive oil, and fish oil) was introduced.

Minimal enteral feeding with maternal milk, or pasteurized donor milk when maternal milk was unavailable, was initiated within the first 24 hours of life. Upon reaching 80 mL/kg/day of enteral intake, human milk was fortified (Aptamil BMF) to provide additional protein and long-chain polyunsaturated fatty acids, including docosahexaenoic acid (DHA) and arachidonic acid (AA).

Parenteral lipid administration was discontinued when enteral intake reached 90-100 mL/kg/day. Amino acids and glucose infusion were adjusted according to standard clinical practice.

Plasma sample collection

Venous or capillary blood samples (0.5-1 mL) were collected longitudinally at five predefined timepoints and integrated with routine clinical care to minimize procedural burden. The first sample (T0) was obtained within 40 minutes after birth during placement of the umbilical venous catheter. Subsequent samples were collected at 48-72 hours of life (T1), 7 days of life (±1 day; T2), approximately 33 weeks postmenstrual age (T3), and at term-equivalent age (~40 weeks postmenstrual age; T4). When available, the umbilical venous catheter was used for early sampling; otherwise, peripheral venipuncture was performed. Samples at T3 and T4 were obtained via peripheral venipuncture.

Whole blood was collected into EDTA tubes and processed within 3 hours of collection. Plasma was isolated by centrifugation at 1200 × g for 15 minutes at room temperature. The supernatant was aliquoted, anonymized using alphanumeric identifiers, and stored at –80 °C until extracellular vesicle enrichment. Samples underwent a single freeze-thaw cycle for analysis.

For method optimization and technical validation experiments, anonymized pooled plasma from healthy adult donors was used. Individual plasma units were combined to generate homogeneous pooled material, which was aliquoted and processed in four independent technical replicates under identical experimental conditions. These pooled samples were used exclusively for workflow benchmarking and reproducibility assessment and were not included in longitudinal clinical analyses.

Automated extracellular vesicle enrichment and integrated proteomic-lipidomic sample preparation

EVs were enriched from plasma using a semi-automated SAX magnetic bead workflow adapted from the Mag-Net method[14] to enable parallel proteomic and lipidomic extraction from minimal

input volumes. All steps were performed on a KingFisher™ Apex magnetic handling station
(Thermo Fisher Scientific) at 4 °C.

For each sample, 10 µL of plasma were thawed on ice and mixed with 40 µL PBS and 50 µL Bis-
Tris Propane (BTP) binding buffer (100 mM BTP, pH 6.3, 150 mM NaCl), yielding a final volume of
100 µL. EV capture was performed using 10 µL of MagReSyn™ SAX magnetic beads (ReSyn
Biosciences), pre-equilibrated in BTP wash buffer (50 mM BTP, pH 6.5, 150 mM NaCl). Sequential
washes were performed to remove non-vesicular plasma components.

Bead-bound EVs were subjected to monophasic extraction using 600 µL 1-
butanol/acetonitrile/water (3:1:1, v/v)[15]. This step promotes membrane disruption and the
subsequent release of the molecular cargo. Samples were incubated overnight at –20 °C to induce
protein precipitation and aggregation capture (PAC), while lipid species remained in the soluble
organic phase.

The following day, samples were reprocessed on the KingFisher™ Apex platform. During the initial
protein aggregation capture (PAC) step, the precipitated proteins were retained on the magnetic
beads, while the lipid-rich supernatant was recovered and processed separately. The lipid fraction
was clarified by centrifugation (4 °C, 4,000 × g, 25 min), transferred to clean tubes, vacuum-dried,
and stored at –20 °C until LC-MS/MS analysis.

In parallel, the bead-bound proteins underwent automated processing, including sequential washes
with acetonitrile (ACN), 70% ethanol, and isopropanol (IPA) to remove contaminants. On-bead
digestion was performed in 100 mM Tris-HCl (pH 8.0) containing 10 mM tris(2-
carboxyethyl)phosphine (TCEP) and 4 mM chloroacetamide (CAA) for reduction and alkylation.
Proteins were digested at 37 °C for 4 h using LysC (Wako) and trypsin (Promega) at enzyme-to-
protein ratios of 1:400 and 1:200 (w/w), respectively. Peptides were acidified with 10 µL of 2% (v/v)
trifluoroacetic acid (TFA) and stored at –20 °C until LC-MS/MS analysis.

Data acquisition

Lipidomic LC-MS/MS acquisition. Lipidomic analyses were performed using a Vanquish Horizon
UHPLC system coupled to an Orbitrap Fusion™ Tribrid™ mass spectrometer (Thermo Fisher
Scientific). Dried lipid extracts were reconstituted in 1-butanol (BuOH)/isopropanol (IPA)/water
(H_2O) (8:23:69, v/v) supplemented with 5 mM phosphoric acid, and 5 µL of each sample were
injected onto a reversed-phase column.

Chromatographic separation was achieved on an ACQUITY UPLC BEH C18 column (2.1 × 50
mm, 1.7 µm; Waters) maintained at 65 °C, using a 7-minute gradient at a flow rate of 600 µL/min.
Mobile phase A consisted of 10 mM ammonium formate in 60:40 ACN/H_2O with 0.1% formic acid
(FA); mobile phase B consisted of 10 mM ammonium formate in 90:10 IPA/ACN with 0.1% FA. The
gradient started at 15% B, increased to 30% B over 1 minute, then to 100% B over the following 5

minutes, and was held at 100% B for 1 minute. The column was subsequently re-equilibrated for 1
minute.

Eluting lipid species were analyzed by electrospray ionization tandem mass spectrometry (ESI-
MS/MS). For technical validation experiments, data were acquired in both positive and negative
ionization modes using a spray voltage of ±3.5 kV. For the longitudinal clinical dataset, acquisition
was performed in positive ion mode only (+3.5 kV). The inlet capillary temperature was set to 300
°C. Nitrogen was used as sheath and auxiliary gas at flow rates of 30 and 10 arbitrary units (AU),
respectively.

Data were acquired in data-dependent acquisition (DDA) mode, alternating full MS and MS/MS
scans. Full MS survey scans were acquired in the Orbitrap analyzer over a mass range of 70-1000
m/z at 70,000 resolution (at 200 m/z), with an AGC target of $1 \times 10^{\square}$ and a maximum injection time
of 100 ms. Up to five MS/MS events were triggered per MS scan using an isolation window of 1.4
Da and an intensity threshold of $1.6 \times 10^{\square}$. Fragment ion spectra were acquired at 17,500
resolution, with an AGC target of $1 \times 10^{\square}$ and a maximum injection time of 50 ms. Previously
fragmented precursor ions were dynamically excluded for 2 seconds. Higher-energy collisional
dissociation (HCD) was performed using stepped normalized collision energies of 20, 30, and 40.

Proteomic LC-MS/MS acquisition. Proteomic analysis was performed using an Evosep One
chromatographic system coupled to an Orbitrap Exploris™ 480 mass spectrometer (Thermo Fisher
Scientific) equipped with a FAIMS Pro Duo interface.

Peptide digests (20 µL) were loaded onto EvoTips according to the manufacturer's instructions.
Peptide separation was achieved on an Aurora Rapid column (8 cm x 75 µm; IonOpticks)
maintained at 25 °C, using the pre-programmed 60 samples per day (60 SPD) method at a
constant flow rate of 1 µL/min.

Data were acquired in data-independent acquisition (DIA) mode. Full MS scans were acquired at
60,000 resolution over 380-980 m/z, with an automatic gain control (AGC) target of 300% and the
maximum injection time (IT) set to Auto. MS/MS acquisition consisted of 50 DIA windows (15 Da
width with 1 Da overlap) acquired at 15,000 resolution, with injection time set to Auto and a
normalized collision energy of 25%. The FAIMS compensation voltage was set to −45 V at
standard resolution. Data were acquired in profile mode using positive ion polarity.

Data processing and quality control

Lipidomic data processing. Raw lipidomics data were processed using MS-DIAL v5.5 for peak
detection, deconvolution, retention time alignment, and lipid annotation[35]. The resulting master
area table was refined using MS-FLO v1.8 to perform additional deisotoping and to resolve
redundant or duplicated lipid features, thereby improving annotation consistency[36].

The curated table was imported into R v4.5.2 for downstream processing. Putative contaminants

(e.g., chemical reagents, plasticizers, polymer-related compounds, and background signals) were

excluded based on annotation keywords and pattern-based filtering.

Technical reproducibility was assessed using pooled quality control (QC) samples. For each lipid

feature, mean intensity and coefficient of variation (CV) were calculated across QC injections.

Features with CV >30% were removed.

To retain biologically informative species in the longitudinal dataset, a fill-rate filter was applied.

Lipid features were retained if they exhibited ≥70% non-missing values in at least one timepoint.

When multiple features corresponded to the same lipid annotation, a single representative feature

was retained based on highest fill rate, lowest QC CV, and highest mean QC intensity.

Intensity values were log_2-transformed and median-centered to correct for sample-wise technical

variability. Missing values were imputed assuming left-censored missingness using a Gaussian

distribution downshifted by 1.8 standard deviations with a width of 0.3 standard deviations.

Proteomic data processing. Proteomic data processing was performed separately for technical

validation experiments and for the longitudinal clinical dataset using Spectronaut v18 (Biognosys

AG)[37].

For technical validation experiments, raw data were analyzed using the Method Evaluation

workflow to assess identification depth and analytical reproducibility.

For the longitudinal clinical dataset, raw files were processed in directDIA mode with default

settings. Searches were performed against the UniProt human reference proteome with Trypsin/P

and LysC specified as cleavage enzymes, carbamidomethylation (C) as a fixed modification, and

methionine oxidation and protein N-terminal acetylation as variable modifications. False discovery

rate was controlled at 1% at peptide spectrum match (PSM), peptide, and protein group levels

using a target–decoy strategy. Protein inference and filtering were performed using the Identified

(Q-value) setting, and protein quantification was based on MS2-level intensities.

Only the longitudinal dataset underwent downstream data curation in R (v4.5.2). Protein groups

were harmonized to a single representative UniProt accession and gene symbol, prioritizing

reviewed Swiss-Prot entries when available. Proteins were retained if they exhibited ≥70% non-

missing values in at least one timepoint. Intensities (log_2 scale) were median-centered across

samples to correct for sample-wise technical variability.

Missing values in the longitudinal dataset were handled using a hybrid imputation strategy

reflecting different plausible missingness mechanisms in MS-based proteomics.

As missing-at-random (MAR) and missing-not-at-random (MNAR) mechanisms cannot be directly

identified from observed data alone, MNAR was operationally assumed when missingness patterns

were consistent with left-censoring. Specifically, within each timepoint block, proteins exhibiting

very low detection rates were classified as MNAR (proportion of observed values <0.30 when ≥12

samples were available in that timepoint, or <0.40 when <12 samples were available). These
thresholds were selected to conservatively identify features with systematic under-detection while
avoiding over-classification of sparse but potentially informative signals. Missing values not flagged
as MNAR were treated as MAR. MAR values were imputed using structured least squares
adaptive (SLSA) imputation (*imp4p* R package), whereas MNAR values were imputed from a
downshifted Gaussian distribution (mean $-1.8 \times SD$, $SD \times 0.3$) to model signal intensities below the
limit of detection.
616

Data analysis
All statistical analyses were performed in R v4.5.2. Proteomic and lipidomic datasets were
analyzed separately and subsequently integrated using a network-based multi-omics framework.
Longitudinal molecular changes were assessed using per-feature linear mixed-effects models fitted
with the *lmerTest* package. For each protein or lipid, abundance was modeled as a function of
sampling timepoint (T0-T4) and gestational age at birth, with infant identity included as a random
intercept to account for repeated measurements: abundance ~ timepoint + ga_birth + (1 |
infant_id). Timepoint was treated as a categorical factor with T0 as the reference level. Models
were fitted using maximum likelihood (REML = FALSE; optimizer = bobyqa).
A global time effect was assessed using Type-III ANOVA on the timepoint term, as implemented in
lmerTest. For endpoint analyses, the contrast between term-equivalent age (T4) and birth (T0) was
extracted from the model as the coefficient for timepoint T4. Effect sizes were reported as β
coefficients, representing model-estimated differences in log_2-transformed abundance. For
timepoint effects, β corresponds to the log_2 fold-change relative to the reference timepoint (T0),
adjusted for gestational age at birth. P-values were adjusted using the Benjamini-Hochberg
procedure. Features with FDR_global < 0.05 were considered significantly time-regulated.
Features were considered significantly regulated at T4 versus T0 if they met FDR_T4vsT0 < 0.05
and |β| > 0.58, corresponding to an approximate 1.5-fold change on the original abundance scale,
thereby prioritizing biologically meaningful shifts.
636

Cross-omics integration was performed using temporally regulated features (FDR_global < 0.05).
Protein and lipid abundance profiles were z-score standardized, and pairwise Spearman
correlations were computed across matched longitudinal samples. Correlation p-values were
corrected using BH adjustment. Network edges were defined by FDR < 0.05 and $|\rho| \geq 0.35$. The
resulting weighted, undirected network was partitioned using Louvain community detection to
identify cross-omics modules. Modules with fewer than 10 total features were excluded from
downstream analyses.
Associations between molecular modules and clinical outcomes were tested separately for proteins
and lipids using CAMERA gene-set testing within the *limma* framework. Models included the

clinical variable of interest as the main effect, with timepoint and gestational age at birth as covariates. Repeated measurements were accounted for using duplicateCorrelation with infant identity as the blocking factor. P-values were corrected for multiple testing across all module-outcome-layer combinations using the BH procedure. Associations with FDR < 0.05 were considered statistically significant.

Functional enrichment of proteomic clusters and network modules was performed in R using Gene Ontology Biological Process and Reactome pathway databases, using all quantified proteins as background and Benjamini–Hochberg correction (FDR < 0.05). Lipid ontology enrichment was performed using the LION web-based tool, ranking lipid species according to their T4 versus T0 β coefficients and retaining significantly enriched terms (FDR < 0.05).

Data availability

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository[38] with the dataset identifier PXD074778. *During peer review, the dataset can be accessed using the following credentials: Username: reviewer_pxd074778@ebi.ac.uk; Password: Ap7CxD6BMgE6; or via the access token: mMjU7VHYzPW2. These reviewer credentials will be removed prior to publication.*

Code availability

The custom R scripts used to generate the results reported in this study are available from the corresponding author upon request.

References

1.   Ohuma, E. O. *et al.* National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysis. *The Lancet* **402**, 1261–1271 (2023).

2.   Möllers, L. S. *et al.* Metabolic-endocrine disruption due to preterm birth impacts growth, body composition, and neonatal outcome. *Pediatr. Res.* **91**, 1350–1360 (2022).

3.   Heath, R. J., Klevebro, S. & Wood, T. R. Maternal and Neonatal Polyunsaturated Fatty Acid Intake and Risk of Neurodevelopmental Impairment in Premature Infants. *Int. J. Mol. Sci.* **23**, 700 (2022).

4.   Galinsky, R. *et al.* Complex interactions between hypoxia-ischemia and inflammation in preterm brain injury. *Dev. Med. Child Neurol.* **60**, 126–133 (2018).

5.   Panfoli, I. *et al.* Oxidative Stress as a Primary Risk Factor for Brain Damage in Preterm Newborns. *Front. Pediatr.* **6**, 369 (2018).

6.   Lee, A. H. *et al.* Dynamic molecular changes during the first week of human life follow a robust developmental trajectory. *Nat. Commun.* **10**, 1092 (2019).

7.   Théry, C. *et al.* Minimal information for studies of extracellular vesicles 2018 (MISEV2018):
a position statement of the International Society for Extracellular Vesicles and update of the
MISEV2014 guidelines. *J. Extracell. Vesicles* **7**, 1535750 (2018).

8.   Kalluri, R. & LeBleu, V. S. The biology, function, and biomedical applications of exosomes.
Science **367**, eaau6977 (2020).

9.   Young, K., Benny, M., Schmidt, A. & Wu, S. Unveiling the Emerging Role of Extracellular
Vesicle–Inflammasomes in Hyperoxia-Induced Neonatal Lung and Brain Injury. *Cells* **13**, 2094
(2024).

10.   Murphy, C. A. *et al.* Unique Patterns of Circulating Extracellular Vesicles in Preterm Infants
During Adaptation to Extra-Uterine Life. *J. Extracell. Vesicles* **14**, e70064 (2025).

11.   Skotland, T., Ekroos, K., Llorente, A. & Sandvig, K. Quantitative Lipid Analysis of
Extracellular Vesicle Preparations: A Perspective. *J. Extracell. Vesicles* **14**, e70049 (2025).

12.   Kong, F., Upadya, M., Weng, A. S. W., Dalan, R. & Dao, M. Isolating Small Extracellular
Vesicles from Small Volumes of Blood Plasma using size exclusion chromatography and density
gradient   ultracentrifugation: A   Comparative   Study.   Preprint   at
https://doi.org/10.1101/2023.10.30.564707 (2023).

13.   Rai, A. *et al.* Multi-omics identify hallmark protein and lipid features of small extracellular
vesicles circulating in human plasma. *Nat. Cell Biol.* 1–19 (2025) doi:10.1038/s41556-025-01795-
7.

14.   Wu, C. C. *et al.* Enrichment of extracellular vesicles using Mag-Net for the analysis of the
plasma proteome. *Nat. Commun.* **16**, 5447 (2025).

15.   Muehlbauer, L. K. *et al.* Rapid Multi-Omics Sample Preparation for Mass Spectrometry.
Anal. Chem. **95**, 659–667 (2023).

16.   Olin, A. *et al.* Stereotypic Immune System Development in Newborn Children. *Cell* **174**,
1277-1292.e14 (2018).

17.   Zhong, W. *et al.* The development of blood protein profiles in extremely preterm infants
follows a stereotypic evolution pattern. *Commun. Med.* **3**, 107 (2023).

18.   Lozano-Andrés, E. *et al.* Physical association of low density lipoprotein particles and
extracellular vesicles unveiled by single particle analysis. *J. Extracell. Vesicles* **12**, 12376 (2023).

19.   Karimi, N. *et al.* Detailed analysis of the plasma extracellular vesicle proteome after
separation from lipoproteins. *Cell. Mol. Life Sci.* **75**, 2873–2886 (2018).

20.   Bennike, T. B. *et al.* Preparing for Life: Plasma Proteome Changes and Immune System
Development During the First Week of Human Life. *Front. Immunol.* **11**, 578505 (2020).

21.   Phuyal, S. *et al.* The Ether Lipid Precursor Hexadecylglycerol Stimulates the Release and
Changes the Composition of Exosomes Derived from PC-3 Cells. *J. Biol. Chem.* **290**, 4225–4237
(2015).

22. Simbari, F. *et al.* Plasmalogen enrichment in exosomes secreted by a nematode parasite
versus those derived from its mouse host: implications for exosome stability and biology. *J.*
Extracell. Vesicles **5**, 30741 (2016).

23. Sódar, B. W. *et al.* Low-density lipoprotein mimics blood plasma-derived exosomes and
microvesicles during isolation and detection. *Sci. Rep.* **6**, 24316 (2016).

24. Flaherty, S. E. *et al.* A lipase-independent pathway of lipid release and immune modulation
by adipocytes. *Science* **363**, 989–993 (2019).

25. Huang, P. *et al.* Complement C3a induces axonal hypomyelination in the periventricular
white matter through activation of WNT/β-catenin signal pathway in septic neonatal rats
experimentally induced by lipopolysaccharide. *Brain Pathol.* **30**, 495–514 (2020).

26. Ten, V. S. *et al.* C1q-Deficiency Is Neuroprotective Against Hypoxic-Ischemic Brain Injury in
Neonatal Mice. *Stroke* **36**, 2244–2250 (2005).

27. Ten, V. S. *et al.* Complement Component C1q Mediates Mitochondria-Driven Oxidative
Stress in Neonatal Hypoxic–Ischemic Brain Injury. *J. Neurosci.* **30**, 2077–2087 (2010).

28. Pedroni, S. M. A. *et al.* Complement inhibition and statins prevent fetal brain cortical
abnormalities in a mouse model of preterm birth. *Biochim. Biophys. Acta BBA - Mol. Basis Dis.*
1842, 107–115 (2014).

29. Liddelow, S. A. *et al.* Neurotoxic reactive astrocytes are induced by activated microglia.
Nature **541**, 481–487 (2017).

30. Starke, N. *et al.* Extracellular Vesicle ASC: A Novel Mediator for Lung–Brain Axis in
Preterm Brain Injury. *Am. J. Respir. Cell Mol. Biol.* **71**, 464–480 (2024).

31. Lal, C. V. *et al.* Exosomal microRNA predicts and protects against severe
bronchopulmonary dysplasia in extremely premature infants. *JCI Insight* **3**, e93994 (2018).

32. Tóth, E. Á. *et al.* Formation of a protein corona on the surface of extracellular vesicles in
blood plasma. *J. Extracell. Vesicles* **10**, e12140 (2021).

33. Dietz, L. *et al.* Uptake of extracellular vesicles into immune cells is enhanced by the protein
corona. *J. Extracell. Vesicles* **12**, e12399 (2023).

34. Muraoka, S. *et al.* Comprehensive proteomic profiling of plasma and serum
phosphatidylserine-positive extracellular vesicles reveals tissue-specific proteins. *iScience* **25**,
104012 (2022).

35. Tsugawa, H. *et al.* MS-DIAL: data-independent MS/MS deconvolution for comprehensive
metabolome analysis. *Nat. Methods* **12**, 523–526 (2015).

36. DeFelice, B. C. *et al.* Mass Spectral Feature List Optimizer (MS-FLO): A Tool To Minimize
False Positive Peak Reports in Untargeted Liquid Chromatography–Mass Spectroscopy (LC-MS)
Data Processing. *Anal. Chem.* **89**, 3250–3255 (2017).

37.   Bruderer, R. *et al.* Extending the Limits of Quantitative Proteome Profiling with Data-
Independent Acquisition and Application to Acetaminophen-Treated Three-Dimensional Liver
Microtissues. *Mol. Cell. Proteomics* **14**, 1400–1410 (2015).
38.   Perez-Riverol, Y. *et al.* The PRIDE database at 20 years: 2025 update. *Nucleic Acids Res.*
53, D543–D553 (2025).

Author contributions

C.L. and A.P. conceived and designed the study. N.G. and F.A. performed the experiments and
curated the dataset. N.G. optimized the workflow, conducted the bioinformatic and statistical
analyses, and drafted the manuscript. F.A. and M.Ba. contributed to data interpretation. L.R. and
S.S. contributed to sample processing and data acquisition. G.T., C.A., F.V., and L.A.R.
contributed to patient recruitment, clinical data collection, and clinical interpretation. G.L. and
M.Bru. contributed to data interpretation and critically revised the manuscript. L.A.R., C.L., and
A.P. jointly supervised the study. All authors reviewed and approved the manuscript.

Competing interests

770 The authors declare no competing interests.

Figure legends

Fig.1: Technical validation of the EV-based multi-omics workflow using plasma micro-
volumes. (a) Mean peptide and protein group identifications obtained from 5 µL and 10 µL plasma
inputs following EV enrichment and monophasic solvent extraction with 1-butanol/acetonitrile/water
(3:1:1, v/v; BAMM), isopropanol (IPA), or methanol (MeOH), compared to the standard Mag-Net
protocol. Dots represent technical replicates; bars indicate mean values. "Neat" denotes direct
plasma digestion without EV enrichment. (b) Distribution of coefficients of variation (CV) for
quantified protein groups across conditions. Bars indicate the proportion of proteins within
predefined CV ranges. (c) Scatter plots of $\log_2$-transformed protein intensities comparing each
extraction condition with the corresponding standard Mag-Net reference at matched plasma input.
Pearson correlation coefficients (r) are shown; dashed lines indicate the identity line. (d) $\log_2$ fold
change (EV/Neat) is shown for representative enriched EV core markers and depleted abundant
plasma proteins under BAMM 10 µL and Mag-Net standard 10 µL conditions. (e) Lipidomic depth
after application of an intensity threshold ($>1\times10^\square$). Mean numbers of detected lipid species in
negative and positive ionization modes across extraction strategies and plasma input volumes.
Dots represent technical replicates; bars indicate mean values. QC denotes pooled quality control
samples. (f) Distribution of CV (%) for quantified lipid species in negative and positive polarity.
Dashed vertical lines indicate 20% and 30% CV thresholds.

Fig. 2: Longitudinal study design and plasma EV multi-omics profiling in very preterm
infants. (a) Overview of the longitudinal cohort, sampling timeline, and analytical workflow. Plasma
samples were collected from very preterm infants born at <32 weeks of gestational age (n = 16) at
five timepoints spanning birth to term-equivalent age: birth (T0), 48-72 hours (T1), 7 days (T2), 33
weeks postmenstrual age (T3), and 40 weeks postmenstrual age (T4, n = 10). EVs were enriched
from plasma, followed by parallel isolation of EV-associated proteins and lipids from the same
sample. Proteomic and lipidomic profiles were generated by LC-MS/MS and processed through
standardized pipelines. (b) Dynamic range of the plasma EV proteome shown as a rank-
abundance plot of median $\log_2$ protein abundance across all samples, highlighting representative
EV-associated proteins. (c) Subcellular localization enrichment analysis of the EV proteome based
on the Jensen COMPARTMENTS database. Terms are ordered by associated protein count along
the x axis. Dot size reflects statistical significance ($-\log_{10}$ FDR), while color intensity indicates odds
ratio. (d) Distribution of identified lipid species across major lipid categories, including
glycerophospholipids, glycerolipids, sphingolipids, fatty acyls, and sterol lipids.
805
Fig. 3: Coordinated longitudinal remodeling of the plasma EV proteome from birth to term-
equivalent age. (a) Circular heatmap illustrating the 875 EV proteins with a significant temporal
profile (LMM; FDR < 0.05). Data are shown as row z-scores of median protein abundances across
five postnatal timepoints, from birth (T0) to term-equivalent age (TEA, T4). Hierarchical clustering
resolved four primary modules; the outer ring indicates the direction of the net developmental shift
(T4 vs T0). (b) Cluster-specific temporal trajectories. Profile plots show z-scored abundances for
individual proteins (thin lines) and cluster medians (bold lines), highlighting coordinated decreasing
(clusters 1A, 1B) and increasing (clusters 2A, 2B) proteomic programs (n indicates protein count
per cluster). (c) Volcano plot displaying the differential protein abundance between TEA (T4) and
birth (T0) derived from the LMM. Statistical significance ($-\log10$ FDR) is plotted against the effect
size (β coefficient). Significant features (FDR < 0.05 and |β| > 0.58) are highlighted, with counts of
downregulated (blue, 439) and upregulated (red, 127) proteins indicated. (d) Longitudinal profiles
of representative EV-associated proteins. Boxes represent median and interquartile range;
whiskers indicate data range. (e) Functional enrichment analysis of significantly downregulated
(left) or upregulated proteins (right) at TEA. Top enriched terms from Gene Ontology (Biological
Process) and Reactome databases are ranked by statistical significance ($-\log10$ FDR). Dot size
reflects the number of proteins associated with each term.
823
Fig. 4: Coordinated structural and metabolic maturation of the plasma EV lipidome. (a)
Heatmap of the 100 lipid species showing a significant temporal profile in the longitudinal linear
mixed-effects model (LMM; FDR < 0.05). Data are represented as row z-scores of median
abundances across five postnatal timepoints (T0-T4). Hierarchical clustering identifies four distinct

longitudinal trajectories; the right-side annotation indicates the direction of change at term-
equivalent age (TEA, T4) relative to birth (T0). (b) Cluster-specific temporal trajectories and
compositional analysis. Profile plots (left) show z-scored abundances for individual lipids (thin
lines) and cluster medians (bold lines). The distribution of lipid classes within each cluster is shown
as pie charts (right). (c) Volcano plot displaying differential lipid abundance between TEA (T4) and
birth (T0). Statistical significance (–log10 FDR) is plotted against the effect size (β coefficient).
Significant features (FDR < 0.05, |β| > 0.58) are highlighted, with counts of upregulated (red, 41)
and downregulated (green, 22) lipids indicated. (d) Lipid ontology (LION) enrichment analysis
based on the β coefficient (T4 vs T0). Enrichment scores are represented as lollipop plots, where
dot size reflects the number of annotated lipid species and color intensity indicates statistical
significance (–log10 FDR). (e) Structural space distribution of regulated phosphatidylcholines (PC),
ether-linked phosphatidylcholines (PC O-), and sphingomyelins (SM). Lipids are mapped according
to the number of carbons in the side chain (x-axis) and degree of unsaturation (y-axis). Dot size
reflects statistical significance (–log10 FDR) and color encodes effect size (T4 vs T0), highlighting
selective structural redistribution across postnatal development.

Fig. 5: Cross-omics integration of the plasma EV proteome and lipidome. (a) Schematic
overview of the cross-omics integration strategy. Temporally regulated EV proteins (n = 875) and
lipids (n = 100), identified by longitudinal linear mixed-effects modeling (LMM), were integrated
using a protein-lipid correlation network based on Spearman correlations across paired longitudinal
samples. Louvain community detection was applied to identify cross-omics modules, which were
subsequently tested for associations with clinical outcomes. (b) Distribution of Spearman
correlation coefficients (ρ) for all protein-lipid pairs. Only significant edges (FDR < 0.05 and |ρ| ≥
0.35) were retained for network construction. (c) Composition of the five cross-omics modules (M1-
M5) by molecular layer (protein vs lipid). Bars indicate the relative contribution of proteins and
lipids within each module, with total node counts reported above each bar. (d) Functional
enrichment analysis of the protein components within each module based on the Gene Ontology
Biological Process database. Terms are ranked by –log10(FDR) and colored by module
assignment.

Fig. 6: Integrated EV modules show significant associations with clinical phenotypes in
preterm infants. (a) Heatmap summarizing module-level associations between EV molecular
modules and clinical outcomes, assessed using a CAMERA-based competitive gene set
framework. Protein (top) and lipid (bottom) groups within each module were tested separately.
Colors represent signed –log10(p-values), with red indicating positive associations and blue
negative associations; asterisks denote associations significant after global FDR correction. Any
brain lesion includes both hemorrhagic brain injury and white matter injury. While only a limited

number of individual lipid species reached statistical significance after multiple testing, coordinated
shifts across lipid modules were detected at the module level, highlighting the ability of module-
based approaches to capture distributed but consistent EV molecular patterns. (b–d) Longitudinal
trajectories of representative leading-edge candidates illustrating the molecular programs
underlying significant module–outcome associations. Lines represent mean ± s.e.m. across
timepoints (T0–T4).

a Proteomics depth

Peptides

Condition	Mean IDs
Mag-Net BAMM 10µL	5707
Mag-Net BAMM 5µL	5666
Mag-Net IPA 10µL	5839
Mag-Net IPA 5µL	5560
Mag-Net MeOH 10µL	5434
Mag-Net MeOH 5µL	5300
Mag-Net standard 10µL	4592
Mag-Net standard 5µL	4417
Neat	2184

Protein groups

Condition	Mean IDs
Mag-Net BAMM 10µL	944
Mag-Net BAMM 5µL	878
Mag-Net IPA 10µL	992
Mag-Net IPA 5µL	912
Mag-Net MeOH 10µL	883
Mag-Net MeOH 5µL	869
Mag-Net standard 10µL	866
Mag-Net standard 5µL	792
Neat	308

b Proteomics reproducibility (CV distribution)

CV group
- 0–10%
- 10–20%
- 20–30%
- >30%

c Proteomics comparability to standard Mag-Net

	BAMM	IPA	MeOH
10 µL input	r = 0.90	r = 0.89	r = 0.89
5 µL input	r = 0.93	r = 0.93	r = 0.95

Test condition ($\log_2$ intensity) vs Mag-Net standard ($\log_2$ intensity)

d EV protein signature

- EV core markers *(enriched)*
- Abundant plasma proteins *(depleted)*

$\log_2$ (EV / Neat)

Mag-Net BAMM 10µL / Mag-Net standard 10µL

TF, ORM1, ORM2, HP, A2M, SERPINA1, ALB, C3, AHSG, HBA1, APOD, HBB, APOA1, APOC1, HPR, FLOT2, FLOT1, ADAM10, PDCD6IP, CLTC, RAB7A, LGALS3BP, ITGB1, RAB27B, RAN, ITGB3, GAPDH, RAP1B, ITGA2B

e Lipidomics depth (Intensity > 10⁵)

Negative polarity

Condition	Mean IDs
Mag-Net BAMM 10µL	80
Mag-Net BAMM 5µL	72
Mag-Net IPA 10µL	78
Mag-Net IPA 5µL	66
Mag-Net MeOH 10µL	84
Mag-Net MeOH 5µL	78
QC	102

Positive polarity

Condition	Mean IDs
Mag-Net BAMM 10µL	261
Mag-Net BAMM 5µL	230
Mag-Net IPA 10µL	211
Mag-Net IPA 5µL	239
Mag-Net MeOH 10µL	106
Mag-Net MeOH 5µL	230
QC	287

f Lipidomics reproducibility (CV distributions)

Negative polarity / Positive polarity

- Mag-Net MeOH 5µL
- Mag-Net MeOH 10µL
- Mag-Net IPA 5µL
- Mag-Net IPA 10µL
- Mag-Net BAMM 5µL
- Mag-Net BAMM 10µL

CV (%)

a

1. Longitudinal LMM analysis
(temporally regulated features)

Temporally regulated proteins
Feature count: 875

Temporally regulated lipids
Feature count: 100

2. Protein-lipid correlation network

Spearman correlations across paired longitudinal samples

3. Cross-omics module correlation
Louvain community detection

4. Module-level clinical association testing

Module 1
Module 2
Module 3
Module 4
Module 5

Statistical association testing

Clinical outcomes

Brain lesions

Sepsis

Mechanical ventilation

b

Negative   Positive

Number of protein–lipid pairs

Edges used for network
FDR < 0.05 & |ρ| ≥ 0.35

Total tests: 87,500
Edges retained: 9,087
Negative: 4,146
Positive: 4,941
Median |ρ|: 0.4
ρ range: [-0.68, 0.73]

Spearman correlation coefficient (ρ)

c

Protein   Lipid

Module composition

n=237   n=235   n=165   n=131   n=115

P=223   P=189   P=151   P=115   P=105

L=14   L=46   L=14   L=16   L=10

M1   M2   M3   M4   M5

d

$-\log_{10}$(FDR)

M1: Protein turnover
M2: Endocytosis & immune interaction
M3: Adaptive immunity
M4: Translation & humoral immunity
M5: ECM remodeling & tissue repair

Macromolecule catabolic process
Ubiquitin-dep. protein catabolic process
Protein deneddylation
Telomerase rna localization to cajal body
Telomerase rna localization
Endocytosis
Import into cell
Immune effector process
Complement activation
Bio process involved in interaction with host
Adaptive immune response
Immunoglobulin mediated immune response
Lymphocyte mediated immunity
Cytoplasmic translation
Peptide catabolic process
Cytoplasmic translation
Humoral immune response
Blood coagulation
Coagulation
Hemostasis
Extracellular matrix organization
Response to wounding
Cell-substrate adhesion
Regulation of body fluid levels
Blood coagulation